Authors: Sharon Salt, Editor
This week’s industry news round-up reveals the latest updates including a new medicine for migraine, a rescheduling of cannabidiol for epilepsy and a successful Phase III trial for neuromyelitis optica spectrum disorder. Find out more about our selection of the highlights below.
Our selection of the highlights includes:
Emgality™ receives marketing authorization for the prevention of migraine
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Emgality™ (galcanezumab), a monoclonal antibody for the prevention of migraine.